Lorus Therapeutics Inc. announced that the annual and special meeting of shareholders to be held on November 30, 2009, to considering and, if deemed appropriate, adopting, with or without variation, a special resolution (the full text of which is reproduced as Appendix 'B; of the Circular) for an amendment to the Corporation's articles of incorporation to consolidate its issued and outstanding common shares on the basis of a ratio within the range of one post-consolidation Share for every 10 (ten) pre-consolidation Shares to one post-consolidation Share for every 50 (fifty) pre-consolidation Shares, with the ratio to be selected and implemented by the Board of Directors in its sole discretion, if at all, at any time prior to November 30, 2010.

Lorus Therapeutics Inc., Special/Extraordinary Shareholders Meeting, Nov 30, 2009, at 10:00 US Eastern Time. Location: The St. Andrew's Club & Conference Centre, 150 King Street West, 16th Floor (Conservatory Lounge), Toronto,Canada. Agenda: To approve the financial statements of the corporation for the financial year ended May 31, 2009, including the auditors' report; to approve the election of directors; to appoint the KPMG LLP as auditors of the corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; to approve the adoption of an alternate compensation plan as more specifically set out in Appendix 'A' of the accompanying Management proxy circular; and to amendment to the corporation's articles of incorporation to consolidate its issued and outstanding common shares on the basis of a ratio within the range of one post-consolidation Share for every 10 pre-consolidation shares to one post-consolidation share for every 50 pre-consolidation shares, with the ratio to be selected and implemented by the Board of Directors in its sole discretion, if at all, at any time prior to November 30, 2010. .

Lorus Therapeutics Inc. announced earnings results for the First Quarter ended August 31, 2009. For the quarter, the company reported revenue of CAD 49,000 compared to CAD 3,000 for the same period a year ago. Loss from operations for the period was CAD 1,246,000 compared to CAD 2,662,000 for the same period a year ago. Net earnings and other comprehensive income for the period was CAD 9,760,000 or CAD 0.04 per basic share compared to net loss and other comprehensive loss of CAD 2,212,000 or CAD 0.01 per basic share for the same period a year ago. The decrease in loss from operations for the three months ended August 31, 2009 compared with the same period in the prior year is due primarily to lower research and development costs of CAD 685,000 resulting from less spending on related activities, and higher expenditures in the prior period for GLP-toxicity studies for LOR-2040 and LOR-253; lower general and administrative costs of CAD 261,000 due to reduced personnel and legal costs; and lower accretion and interest expense related to the convertible debentures as a result of repurchasing the debentures in June 2009.